AXIM
AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 0.00 | $0 | -$673,590 |
| 2025 Q1 | -0.00 | $0 | -$133,061 |
| 2024 Q4 | -0.00 | $0 | -$78,030 |
| 2024 Q3 | -0.00 | $0 | -$262,980 |
| 2024 Q2 | -0.01 | $17,479 | $553,013 |
| 2024 Q1 | -0.00 | $52,979 | -$1M |
| 2023 Q4 | -0.01 | $12,859 | $19,556 |
| 2023 Q3 | 0.00 | $9,581 | -$264,503 |